Breaking Corporate Events, Analysed in Real Time

Glenmark Pharmaceuticals Advances Phase 3 Trial for Trastuzumab rezetecan in Ovarian Cancer

Glenmark Specialty S.A. has advanced its multi-country Phase 3 clinical trial for Trastuzumab rezetecan, a HER2-targeted antibody-drug conjugate. India marks the initial site for patient enrollment following DCGI approval, with further expansion planned for Australia and South Korea.

Glenmark Pharmaceuticals Launches Lacosamide Injection in USA Targeting $15.2M Market

Glenmark Pharmaceuticals Inc., USA, has announced the commercial launch of Lacosamide Injection USP, a generic version of Vimpat®. This move expands the company's injectable portfolio in the United States, targeting a market with approximately $15.2 million in annual sales as of April 2026.